Galapagos to Share $1.675B Ouro Medicines Acquisition Costs for 20–23% Royalties
Galapagos will fund half of Gilead’s $1.675 billion upfront payment and up to $500 million in milestone payments to acquire Ouro Medicines, absorbing its operating assets and retaining its team. The agreement secures Galapagos a 20–23% royalty on global net sales of OM336 and frees €500 million for share repurchases or other uses.
1. Acquisition and Collaboration
Galapagos and Gilead have agreed that Galapagos will fund 50% of the $1.675 billion upfront and up to $500 million in milestone payments for Gilead’s acquisition of Ouro Medicines, absorbing all operating assets and retaining the current workforce. Gilead retains sole commercialization rights worldwide except Greater China.
2. Drug and Development Status
The deal centers on OM336, a BCMAxCD3 T-cell engager granted Fast Track and Orphan Drug designations, currently in Phase 1/2 trials for severe autoimmune conditions. OM336 has demonstrated rapid B cell depletion and efficacy signals in autoimmune hemolytic anemia and immune thrombocytopenia.
3. Financial Terms and Royalties
Under the agreement, Galapagos will be responsible for development costs through registrational study initiation, with subsequent costs shared equally, and will receive 20–23% royalties on net sales. Additionally, up to €500 million of Galapagos’ existing cash becomes unrestricted, including allowances for share repurchases.
4. Strategic Implications
This transaction bolsters Galapagos’ inflammation portfolio by adding a late-stage autoimmune asset while preserving capital flexibility. The collaboration also updates legacy agreements, enhancing Galapagos’ strategic optionality and potential value creation from joint development milestones.